Diligence memo · auto-generated · as of July 2, 2026
Persevere Therapeutics Inc.
Persevere Therapeutics Inc. looks fair against its niche peers and is active on financing cadence.
Businessfiled
Persevere Therapeutics Inc. operates in Pharma, based in CHESTERBROOK.
Sub-sector tags: pharma.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Persevere Therapeutics Inc. has raised $1.6M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $1.6M on 2026-02-11.
Most recent recorded round closed around 2026-02-11.
Valuation (modeled)modeled
Provath models Persevere Therapeutics Inc. at approximately $3.2M (range $1.2M–$5.6M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 0.84× the median modeled value of Seed Pharma companies in 2025–2027 (9 peers) — value vs value, same stage and era. Within the normal band (84% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 5 mo ago; this sector typically re-raises about every 16 months.
Raising on or ahead of the sector's normal rhythm.
Comparablesmixed
Capital scale ranks ahead of 41% of Pharma peers (310 compared).
Modeled value ranks above 24% of those peers.
Closest niche peers: Antigenix Therapeutics, Inc., Strategikon Pharma, Inc., Fitness Fingerprint Therapeutics, Inc., NeuroEM Therapeutics, Inc., iQure Pharma Inc..
Peoplefiled
1 named person on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.